Associate Professor, Pharmacology
Professor, BIO5 Institute
Director, Aribi Institute
Professor, Biomedical Engineering
Professor, Biomedical Engineering - GIDP
Professor, Physiological Sciences - GIDP
Dr. Ronald Lynch is Associate Director of Shared Resources. As part of that role, he has oversight of the Cancer Center’s 10 shared resources (core facilities) which includes monitoring performance, needs assessment, and expansion of new service capabilities.
Dr. Lynch received a Bachelor of Science degree in Chemistry from the University of Miami, and a PhD in Physiology and Biophysics from the University of Cincinnati. He began training in optical imaging and MR spectroscopy of cardiovascular and renal--from the region of the kidneys--metabolism in 1984 while at the NIH under the direction of Dr. Robert S. Balaban. In 1987 Dr. Lynch moved to a staff position in the Biomedical Imaging Group and Physiology Department at the University of Massachusetts Medical Center and in 1990 was recruited to the University of Arizona to develop a research program centered on the use and development of microscopic imaging and spectroscopy to study physiological problems. In 2000, Dr. Lynch was a visiting scientist at the NIH Laboratory of Functional and Molecular Imaging and the Magnetic Resonance Imaging Center with Dr. Alan Koretsky.
Dr. Lynch’s primary appointment is in Physiology, with joint appointments in Biomedical Engineering and Medical Pharmacology. He currently is the Director of the Arizona Research Institute for Biomedical Imaging (ARIBI), and is a member of the Arizona Cancer Center and Sarver Heart Center. As part of his duties in the Cancer Center, Dr. Lynch is director of a Cancer Core Imaging Facility. Dr Lynch also is the director of the Advanced Research Institute for Biomedical Imaging (ARIBI) at the University of Arizona.
Research in the Lynch lab focuses on second messenger signaling in vascular smooth muscle cells and nutrient sensing cells (e.g., Pancreatic Beta-cells) with emphasis on alterations in signaling that occur during development of Diabetes. Under development are methods to modify and analyze beta cell mass in order to evaluate the initiation of the pre-diabetic state, and efficacy of its treatment. Analyses of subcellular protein distributions, second messenger signaling, and ligand binding are performed using state of the art microscopy and analysis approaches which is a second area of expertise. Over the past 3 decades, the Lynch lab has worked on developing unique microscopic imaging and spectroscopy approaches to study cell and tissue function, as well as screening assays for cell signaling and ligand binding.
See more at: lynchlab.arizona.edu